Nkarta CMO Kanya Rajangam resigns; David Shook named VP Clinical Development

Nkarta, Inc.

Dr. Kanya Rajangam resigns as CMO effective June 5, 2022, to oversee R&D at a private biotech.
Dr. David Shook appointed VP Clinical Development, leading all clinical and regulatory activities.
Shook is a practicing pediatric hematologist/oncologist and early NK cell therapy pioneer.
Nkarta's NKX101 and NKX019 programs continue; expects to submit updated data for a medical meeting in 2022.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. David Shook

Vice President, Clinical Development

NKTX · Nkarta, Inc.

Filed: May 16, 2022, 7:59 PM ET

On May 16, 2022, the Company issued a press release announcing the resignation of Dr. Rajangam and the appointment of Dr. David Shook as Vice President, Clinical Development.

Departed

Dr. Kanya Rajangam

Chief Medical Officer

NKTX · Nkarta, Inc.

Effective: 2022-06-05
Filed: May 16, 2022, 7:59 PM ET

On May 13, 2022, Dr. Kanya Rajangam notified Nkarta, Inc. (the “Company”) of her decision to resign as Chief Medical Officer of the Company to oversee research and development activities at a private biotechnology company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Dr. David Shook was appointed as Vice President, Clinical Development at Nkarta, Inc..

Action: appointed
Role: Vice President, Clinical Development

Exact text from the filing

On May 16, 2022, the Company issued a press release announcing the resignation of Dr. Rajangam and the appointment of Dr. David Shook as Vice President, Clinical Development.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Kanya Rajangam resigned as Chief Medical Officer at Nkarta, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On May 13, 2022, Dr. Kanya Rajangam notified Nkarta, Inc. (the “Company”) of her decision to resign as Chief Medical Officer of the Company to oversee research and development activities at a private biotechnology company.

View on SEC.gov

Nkarta, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-010075

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.